The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral? Drug-Eluting Balloon in a Chinese Patient Population
研究单位：[1]Medtronic Endovascular[2]Department Anzhen Hospital, Capital Medical University[3]Department 301 Hospital[4]301 Hospital/Chinese PLA General Hospital,Beijing, China[5]Anzhen Hospital, Capital Medical University,Beijing, China[6]Peking University First Hospital,Beijing, China[7]Xuanwu Hospital, Capital Medical University,Beijing, China[8]West China Hospital,Chengdu, China, 610041[9]The First Affiliated Hospital of Chongqing Medical University,Chongqing, China, 400016[10]The First Affiliated Hospital, Dalian Medical University,Dalian, China[11]The First Affiliated Hospital of Fujian Medical University,Fuzhou, China[12]The 1stAffiliated Hospital of Sun Yat-sen University,Guangzhou, China[13]The 2nd Affiliated Hospital of Harbin Medical University,Harbin, China[14]The first affiliated Hospital of Harbin Medical University,Harbin, China[15]Nanjing Drum Tower Hospital,Nanjing, China[16]Shanghai 9th People Hospital Affiliated Shanghai Jiao Tong University School of Medecine,Shanghai, China, 200011[17]Zhongshan Hospital, Fudan University,Shanghai, China[18]Shengjing Hospital of China Medical University,Shenyang, China
The purpose of this study is to confirm that the IN.PACT Admiral is safe and effective for the interventional treatment of new and non-stented restenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in Chinese patients.
